[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. - Wikidata - wikimedia - TriplyDB

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

http://www.wikidata.org/entity/Q34645445

about

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner.Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice Selection of suitable reference genes for normalization of genes of interest in canine soft tissue sarcomas using quantitative real-time polymerase chain reaction.An update on the role of PET/CT and PET/MRI in ovarian cancer.In Vivo Phenotyping of Tumor Metabolism in a Canine Cancer Patient with Simultaneous (18)F-FDG-PET and Hyperpolarized (13)C-Pyruvate Magnetic Resonance Spectroscopic Imaging (hyperPET): Mismatch Demonstrates that FDG may not Always Reflect the Warbu [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized C-MRSI

P2860

Q26742109-A474933D-C4BF-47BD-8564-C830ABB305AF Q26778463-19B42412-9C51-4B96-A51B-A26B11DBD85E Q33889809-0B0DAF0B-DE48-4FBB-8194-499C681E3CB7 Q34987705-7F94C31F-9F52-4E79-AAD3-2AB964384E32 Q35081130-B9A6FA3E-3F26-4042-AF73-622667787857 Q35120054-821EF376-8E43-4558-80D4-FC6C293488EE Q38391024-7C0AA462-05CC-44A0-BAAF-DFD8CF2B99DE Q39127714-0936F687-1C91-4ACD-9808-F7F44BBA94ED Q42048577-66390EE2-B996-446C-812F-B4FBC75096F1 Q55286904-89C1969F-8D42-44C6-B84F-5868DB726612 Q57116080-1CBBD3F3-D715-442A-8EA5-5843A5AE9D1F

P2860

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

http://www.wikidata.org/entity/Q34645445

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@ast

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@en

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@nl

type

label

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@ast

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@en

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@nl

prefLabel

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@ast

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@en

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@nl

P1433

Q34645445-B314967D-5B41-4B8D-989E-ED4166352B73

P1476

Q34645445-C47F2418-4893-41F4-949C-C583B9BC1178

P2093

Q34645445-0AC094B3-E47A-4473-9E30-B1FF8F4C0A24

Q34645445-9E73FDFB-E9D0-45A3-AF0F-1B01E1622AAB

Q34645445-ABB23B44-137B-4C7C-8536-A1B5D2D9B754

Q34645445-B481CFF4-62C9-44C6-941E-46E8B71DCB9F

Q34645445-B6341546-07AF-4AF4-91C4-81E89E3724D0

Q34645445-E9EF2D04-9B15-4F96-AFFD-230F1229C000

P2860

Q34645445-005857BB-4980-4402-9414-EBEADD239853

Q34645445-0190C7B9-1E18-4B5E-892D-4A5F52836BAB

Q34645445-04AD0884-C622-40B2-A17F-DC8B5F4CD679

Q34645445-04E3646B-BD7F-4A70-8D42-0EFD1A92AE47

Q34645445-0879E028-31FB-4D35-8F8E-9403654A017D

Q34645445-09DCF47A-4DB9-4E25-AA24-A402F70A79FB

Q34645445-0A102FD4-C874-4CBB-A086-4C583E9C46AC

Q34645445-16BC889F-3067-4E5C-9AA6-5D3D378911DC

Q34645445-1AA51591-08B0-4345-AE5B-3112C2DD1647

Q34645445-1F258D03-A142-4B98-BB46-1DE6FCE93A83

P2888

Q34645445-61AB5D7D-164B-43C6-8057-DF10D7620A90

P304

Q34645445-E9BBCF99-7A30-412C-AADE-B561ACE8ABE6

P31

Q34645445-A8BE7474-4980-4CE1-AE90-78C506951D7A

P356

Q34645445-5C98CF41-CF75-470D-AFBC-4C3DFE6A3177

P407

Q34645445-FDCA1F6B-004B-463E-9B14-0C400ED5EBE8

P478

Q34645445-EBFE0C0E-4513-47B8-BEE6-25702E01E9D9

P50

Q34645445-7192560D-2CEF-4C69-87A6-DA00B2AC0A9E

Q34645445-8BC0E807-DE46-49B1-A1C1-7373FA4639B7

Q34645445-E86870F0-1A71-496C-8251-08C06E999472

Q34645445-EB5D7976-1B0C-4B35-9B36-6BCE74F67091

P577

Q34645445-287E6B44-BBAD-4371-B452-F4E7E10EBC4F

P5875

Q34645445-A28DFD9A-C2C7-4E82-AA78-A6EEDABEE80E

P6179

Q34645445-4B7300E0-2313-40B8-9657-3E94A03035A3

P698

Q34645445-4996C37F-7E74-4C5D-A153-873E4083F586

P921

Q34645445-5F91B5CC-4792-463E-B3B9-37F0884A32AA

P932

Q34645445-027623E3-384B-49EF-AD6E-81245A6B0769

P356

1471-2407-13-168

P1433

P1476

[18F]FDG and [18F]FLT positron ...... ary cancer xenografts in mice.

@en

P2093

Camilla Bardram Johnbeck

http://www.w3.org/2001/XMLSchema#string

Jacob Madsen

http://www.w3.org/2001/XMLSchema#string

Kamille Dumong Erichsen

http://www.w3.org/2001/XMLSchema#string

Maxwell Sehested

http://www.w3.org/2001/XMLSchema#string

Mette Munk Jensen

http://www.w3.org/2001/XMLSchema#string

Peter Buhl Jensen

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Mammalian deoxyribonucleoside kinases

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice

Regulation of human thymidine kinase during the cell cycle

qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data

Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors.

Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

P2888

1471-2407-13-168

P304

168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-168

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Liselotte Højgaard

Fredrik Björkling

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257872757

http://www.w3.org/2001/XMLSchema#string

P6179

1040402761

http://www.w3.org/2001/XMLSchema#string

P698

23548101

http://www.w3.org/2001/XMLSchema#string

P921

P932

3621527

http://www.w3.org/2001/XMLSchema#string